A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 48
Summary
- Conditions
- •Non-alcoholic Steatohepatitis (NASH)
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Participant)Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 18 years and 50 years
- Gender
- Only males
Description
This is a Phase 1, randomized, first-in-human (FIH) study to assess the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium following subcutaneous (SC) administration in healthy male subjects at increasing single doses
This is a Phase 1, randomized, first-in-human (FIH) study to assess the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium following subcutaneous (SC) administration in healthy male subjects at increasing single doses
Tracking Information
- NCT #
- NCT02612662
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ronald Goldwater, MDCM, M.Sc, CPI PAREXEL Early Phase Clinical Unit Baltimore
Get Well Soon